Research Article
BibTex RIS Cite

0-24 ay arası çocuklarda difteri, boğmaca, tetanoz ve Hepatit B aşıları ile aşılanma durumları ve aşı antikor yanıtları

Year 2022, Volume: 15 Issue: (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı, 101 - 108, 30.06.2022

Ayşe Orman Esat Yılgör

Abstract

Amaç: Aşı ile önlenebilir hastalıklardan olan ‘Difteri, Boğmaca, Tetanoz ve Hepatit B’ eliminasyonu hedefi için çocuklarda en az %90 bağışıklık düzeyine ulaşılması gerekmektedir. Bu araştırmamızda 0-24 ay arası çocukların ve ülkemizde halen kullanılmakta olan difteri-aselüler boğmaca-difteri ve hepatit B aşılarının bu hastalıklara karşı aşı antikor seviyelerinin koruyucu düzeyde olup olmadığını tespit etmeyi ve aşılanma oranlarını değerlendirmeyi amaçladık. Yöntem: Çocuk Sağlığı ve Hastalıkları polikliniğine getirilen 0-24 ay arası sağlıklı çocuklardan basit rastlantısal örnekleme yöntemi ile seçilen 450 çocuk çalışmaya dahil edildi. Her çocuktan asepsi koşullarına uyularak tek kullanımlık plastik enjektörler ile 5 ml venöz kan alındı. Difteri, boğmaca, tetanoz ve hepatit B, serum antikor düzeyleri kantitatif olarak ELISA yöntemi ile ölçüldü. Bulgular: Araştırmaya katılan çocukların %92.6’sı difteriye karşı, %94’ü tetanoza karşı, %80.8’i hepatit B’ye karşı, boğmacaya karşı kesim değeri (10 EU/ml) için %65.4’ü, (4 EU/ml ) için ise %74.1’i seropozitif bulundu. Bu aşıların seropozitifliği üzerine cinsiyet ve aşı uygulama merkezinin etkisi görülmedi. Sonuç: Seropozitifliği en geç oluşan aşı boğmaca aşısı iken en yüksek seropozitiflik sağlayan tetanoz aşısı olmuştur. Toplum bağışıklığını değerlendirmek için belli aralıklarla serolojik araştırmaların yapılması önerilmektedir.

Keywords

Difteri tetanoz boğmaca hepatit B seroloji

References

  • 1. Peck M, Gacic-Dobo M, Diallo MS, Nedelec Y, Sodha SV, Wallace AS. Global Routine Vaccination Coverage, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(42):937-42.
  • 2 Barkin RM, Samuelson JS, Gotlin LP, Barkin SZ. Primary immunization with diphtheria-tetanus toxoids vaccine and diphtheria-tetanus toxoids-pertussis vaccine adsorbed: comparison of schedules. Pediatr Infect Dis. 1985;4(2):168-71.
  • 3 Barkin RM, Pichichero ME, Samuelson JS, Barkin SZ. Pediatric diphtheria and tetanus toxoids vaccine: clinical and immunologic response when administered as the primary series. J Pediatr. 1985;106(5):779-81.
  • 4 Liang JL, Tiwari T, Moro P, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2018;67(2):1-44.
  • 5 Aristegui J, Garrote E, González A, Arrate JP, Perez A, Vandepapelière P. Immune response to a combined hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine administered to infants at 2, 4 and 6 months of age. Vaccine. 1997;15(1):7-9.
  • 6 Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP). MMWR Recomm Rep. 1991;40(Rr-10):1-28.
  • 7 Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J. 2005;24(5 Suppl):S62-5.
  • 8 Storsaeter J, Hallander HO, Gustafsson L, Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine. 2003;21(25-26):3542-9.
  • 9 Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(Rr-7):1-25.
  • 10 Glode M, Joffe L, Reisinger K, Blatter M, Plotkin S, Watson B, et al. Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children. Pediatr Infect Dis J. 1992;11(7):530-5.
  • 11 Tetanus vaccines: WHO position paper – February 2017. Wkly Epidemiol Rec. 2017;92(6):53-76.
  • 12 McQuillan GM, Kruszon-Moran D, Deforest A, Chu SY, Wharton M. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med. 2002;136(9):660-6.
  • 13 General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(2):1-64.
  • 14 Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J. 2003;22(7):628-34.
  • 15 Liu Z, Liu S, Shu Y, et al. Severe Bordetella pertussis infection and vaccine issue in Chongqing, from 2012 to 2018. Int J Infect Dis. 2019;84:102-8.
  • 16 De Greeff SC, Mooi FR, Westerhof A, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis. 2010;50(10):1339-45.
  • 17 Wiley KE, Zuo Y, Macartney KK, McIntyre PB. Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. Vaccine. 2013;31(4):618-25.
  • 18 Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol. 2011;204(4):334.e1-5.
  • 19 Hardy-Fairbanks AJ, Pan SJ, Decker MD, et al. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. Pediatr Infect Dis J. 2013;32(11):1257-60.
  • 20 Leuridan E, Hens N, Peeters N, de Witte L, Van der Meeren O, Van Damme P. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J. 2011;30(7):608-10.
  • 21 Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis. 2013;56(4):539-44.
  • 22 Sarathy L, Cirillo C, Dehn C, Lerou PH, Prendergast M. Improving Timeliness of Hepatitis B Vaccine Birth Dose Administration. Hosp Pediatr. 2021;11(5):446-53.
  • 23 Maiorella R, Rodriguez VA. Hepatitis B Vaccine Refusal in the Newborn Period. Pediatr Ann. 2021;50(8):e343-e7.
  • 24 McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390-6.
  • 25 Van den Ende C, Marano C, van Ahee A, Bunge EM, De Moerlooze L. The immunogenicity of GSK's recombinant hepatitis B vaccine in children: a systematic review of 30 years of experience. Expert Rev Vaccines. 2017;16(8):789-809.
  • 26 Li X, Xu Y, Dong Y, et al. Monitoring the efficacy of infant hepatitis B vaccination and revaccination in 0-to8-year-old children: Protective anti-HBs levels and cellular immune responses. Vaccine. 2018;36(18):2442-9

Year 2022, Volume: 15 Issue: (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı, 101 - 108, 30.06.2022

Ayşe Orman Esat Yılgör

Abstract

References

  • 1. Peck M, Gacic-Dobo M, Diallo MS, Nedelec Y, Sodha SV, Wallace AS. Global Routine Vaccination Coverage, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(42):937-42.
  • 2 Barkin RM, Samuelson JS, Gotlin LP, Barkin SZ. Primary immunization with diphtheria-tetanus toxoids vaccine and diphtheria-tetanus toxoids-pertussis vaccine adsorbed: comparison of schedules. Pediatr Infect Dis. 1985;4(2):168-71.
  • 3 Barkin RM, Pichichero ME, Samuelson JS, Barkin SZ. Pediatric diphtheria and tetanus toxoids vaccine: clinical and immunologic response when administered as the primary series. J Pediatr. 1985;106(5):779-81.
  • 4 Liang JL, Tiwari T, Moro P, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2018;67(2):1-44.
  • 5 Aristegui J, Garrote E, González A, Arrate JP, Perez A, Vandepapelière P. Immune response to a combined hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine administered to infants at 2, 4 and 6 months of age. Vaccine. 1997;15(1):7-9.
  • 6 Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP). MMWR Recomm Rep. 1991;40(Rr-10):1-28.
  • 7 Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J. 2005;24(5 Suppl):S62-5.
  • 8 Storsaeter J, Hallander HO, Gustafsson L, Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine. 2003;21(25-26):3542-9.
  • 9 Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(Rr-7):1-25.
  • 10 Glode M, Joffe L, Reisinger K, Blatter M, Plotkin S, Watson B, et al. Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children. Pediatr Infect Dis J. 1992;11(7):530-5.
  • 11 Tetanus vaccines: WHO position paper – February 2017. Wkly Epidemiol Rec. 2017;92(6):53-76.
  • 12 McQuillan GM, Kruszon-Moran D, Deforest A, Chu SY, Wharton M. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med. 2002;136(9):660-6.
  • 13 General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(2):1-64.
  • 14 Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J. 2003;22(7):628-34.
  • 15 Liu Z, Liu S, Shu Y, et al. Severe Bordetella pertussis infection and vaccine issue in Chongqing, from 2012 to 2018. Int J Infect Dis. 2019;84:102-8.
  • 16 De Greeff SC, Mooi FR, Westerhof A, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis. 2010;50(10):1339-45.
  • 17 Wiley KE, Zuo Y, Macartney KK, McIntyre PB. Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. Vaccine. 2013;31(4):618-25.
  • 18 Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol. 2011;204(4):334.e1-5.
  • 19 Hardy-Fairbanks AJ, Pan SJ, Decker MD, et al. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. Pediatr Infect Dis J. 2013;32(11):1257-60.
  • 20 Leuridan E, Hens N, Peeters N, de Witte L, Van der Meeren O, Van Damme P. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J. 2011;30(7):608-10.
  • 21 Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis. 2013;56(4):539-44.
  • 22 Sarathy L, Cirillo C, Dehn C, Lerou PH, Prendergast M. Improving Timeliness of Hepatitis B Vaccine Birth Dose Administration. Hosp Pediatr. 2021;11(5):446-53.
  • 23 Maiorella R, Rodriguez VA. Hepatitis B Vaccine Refusal in the Newborn Period. Pediatr Ann. 2021;50(8):e343-e7.
  • 24 McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390-6.
  • 25 Van den Ende C, Marano C, van Ahee A, Bunge EM, De Moerlooze L. The immunogenicity of GSK's recombinant hepatitis B vaccine in children: a systematic review of 30 years of experience. Expert Rev Vaccines. 2017;16(8):789-809.
  • 26 Li X, Xu Y, Dong Y, et al. Monitoring the efficacy of infant hepatitis B vaccination and revaccination in 0-to8-year-old children: Protective anti-HBs levels and cellular immune responses. Vaccine. 2018;36(18):2442-9
There are 26 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Sözlü Bildiriler
Authors

Ayşe Orman This is me

Esat Yılgör This is me

Publication Date June 30, 2022
Submission Date February 26, 2022
Acceptance Date March 10, 2022
Published in Issue Year 2022 Volume: 15 Issue: (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı

Cite

APA Orman, A., & Yılgör, E. (2022). 0-24 ay arası çocuklarda difteri, boğmaca, tetanoz ve Hepatit B aşıları ile aşılanma durumları ve aşı antikor yanıtları. Mersin Üniversitesi Sağlık Bilimleri Dergisi, 15((Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı), 101-108.
AMA Orman A, Yılgör E. 0-24 ay arası çocuklarda difteri, boğmaca, tetanoz ve Hepatit B aşıları ile aşılanma durumları ve aşı antikor yanıtları. Mersin Univ Saglık Bilim derg. June 2022;15((Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı):101-108.
Chicago Orman, Ayşe, and Esat Yılgör. “0-24 Ay Arası çocuklarda Difteri, boğmaca, Tetanoz Ve Hepatit B aşıları Ile aşılanma Durumları Ve aşı Antikor yanıtları”. Mersin Üniversitesi Sağlık Bilimleri Dergisi 15, no. (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı (June 2022): 101-8.
EndNote Orman A, Yılgör E (June 1, 2022) 0-24 ay arası çocuklarda difteri, boğmaca, tetanoz ve Hepatit B aşıları ile aşılanma durumları ve aşı antikor yanıtları. Mersin Üniversitesi Sağlık Bilimleri Dergisi 15 (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı 101–108.
IEEE A. Orman and E. Yılgör, “0-24 ay arası çocuklarda difteri, boğmaca, tetanoz ve Hepatit B aşıları ile aşılanma durumları ve aşı antikor yanıtları”, Mersin Univ Saglık Bilim derg, vol. 15, no. (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı, pp. 101–108, 2022.
ISNAD Orman, Ayşe - Yılgör, Esat. “0-24 Ay Arası çocuklarda Difteri, boğmaca, Tetanoz Ve Hepatit B aşıları Ile aşılanma Durumları Ve aşı Antikor yanıtları”. Mersin Üniversitesi Sağlık Bilimleri Dergisi 15/(Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı (June 2022), 101-108.
JAMA Orman A, Yılgör E. 0-24 ay arası çocuklarda difteri, boğmaca, tetanoz ve Hepatit B aşıları ile aşılanma durumları ve aşı antikor yanıtları. Mersin Univ Saglık Bilim derg. 2022;15:101–108.
MLA Orman, Ayşe and Esat Yılgör. “0-24 Ay Arası çocuklarda Difteri, boğmaca, Tetanoz Ve Hepatit B aşıları Ile aşılanma Durumları Ve aşı Antikor yanıtları”. Mersin Üniversitesi Sağlık Bilimleri Dergisi, vol. 15, no. (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı, 2022, pp. 101-8.
Vancouver Orman A, Yılgör E. 0-24 ay arası çocuklarda difteri, boğmaca, tetanoz ve Hepatit B aşıları ile aşılanma durumları ve aşı antikor yanıtları. Mersin Univ Saglık Bilim derg. 2022;15((Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı):101-8.
 Download Cover Image

MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.

Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.

Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.

Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.

Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.

Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.

154561545815459

Creative Commons Lisansı
This work is licensed with Attribution-NonCommercial 4.0 International.